The best CRISPR stocks depend on your portfolio and investment goals — while volatility can be ideal for day traders, long-term investors will want to look to stocks with steadier gains over time.
7 CRISPR stocks to watch
We round up a selection of stocks in or related to the gene editing industry, weighting the list more heavily towards popular mid- and large-cap US stocks.
Compare online trading platforms by fees, asset types and bonuses to find the best for your investment in CRISPR stocks.
1 - 6 of 6
*Signup bonus information updated weekly.
Take a deeper dive into CRISPR stocks
If you're interested in investing in the gene editing industry, take a closer look at what companies in this industry do and how the stocks have historically performed. Keep in mind that positive past performance doesn't guarantee that a stock will continue to rise in the future.
1. Crispr Therapeutics (CRSP)
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases.
Crispr Therapeutics stock opened the day at $45.56 after a previous close of $45.18. The latest price was $44.16 (25-minute delay). Crispr Therapeutics is listed on the NASDAQ, has a trailing 12-month revenue of around USD1.2 million and employs 458 staff.
Editas Medicine, Inc. , a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology.
Editas Medicine stock opened the day at $56.09 after a previous close of $56.52. The latest price was $54.90 (25-minute delay). Editas Medicine is listed on the NASDAQ, has a trailing 12-month revenue of around USD$19.7 million and employs 226 staff.
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat neovascular age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.
Regeneron Pharmaceuticals stock opened the day at $816.01 after a previous close of $819.35. The latest price was $811.50 (25-minute delay). Regeneron Pharmaceuticals is listed on the NASDAQ, has a trailing 12-month revenue of around USD$12.2 billion and employs 11,851 staff.
Cellectis S. A. , a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.
Cellectis stock opened the day at $15.14 after a previous close of $14.44. The latest price was $15.78 (25-minute delay). Cellectis is listed on the NASDAQ, has a trailing 12-month revenue of around USD$25.7 million and employs 231 staff.
Beam Therapeutics Inc. , a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 and BEAM-102 for the treatment of sickle cell disease beta thalassemia; BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency.
Beam Therapeutics Inc stock opened the day at $100.64 after a previous close of $98.05. The latest price was $100.99 (25-minute delay). Beam Therapeutics Inc is listed on the NASDAQ, has a trailing 12-month revenue of around USD$60.9 million and employs 507 staff.
bluebird bio, Inc. , a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy.
Bluebird bio stock opened the day at $30.43 after a previous close of $30.43. The latest price was $30.57 (25-minute delay). Bluebird bio is listed on the NASDAQ, has a trailing 12-month revenue of around USD$5.1 million and employs 518 staff.
Sangamo Therapeutics, Inc. , a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.
Sangamo Therapeutics stock opened the day at $12.01 after a previous close of $12.01. The latest price was $11.71 (25-minute delay). Sangamo Therapeutics is listed on the NASDAQ, has a trailing 12-month revenue of around USD$111.3 million and employs 478 staff.
Sign up with an online broker or platform to invest in one or more of these CRISPR stocks.
Compare share trading platforms. Use our comparison table to narrow down top brokers by fees and bonuses.
Open and fund your brokerage account. You’ll need personal and financial details, like your contact and bank information.
Search for the stock you're interested in. Find the stock by name or ticker symbol, like CRSP or EDIT.
Decide on how many to buy. Some brokers will allow you to purchase fractional shares, while others require you to purchase whole shares.
Choose an order type. Invest in the CRISPR stocks now with a market order or use a limit order to delay your purchase until the stock reaches your desired price.
Buy the stock. Tap or click the Buy button on your brokerage account. Once you’ve invested in the gene editing industry, track how your stock performs to decide when it’s time to sell.
Bottom line
While it’s possible to turn a profit investing in CRISPR stocks, keep in mind that — like any investment — CRISPR stocks are not immune to risk. These stocks are subject to fluctuating conditions — both in the market and in the gene editing industry, so carefully vet your picks before you invest. And if you’re new to investing, or if it’s been awhile since you’ve taken a critical look at your investing accounts, compare brokers to make sure you’re getting the best features in your trading account.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an adviser or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
How likely would you be to recommend finder to a friend or colleague?
0
1
2
3
4
5
6
7
8
9
10
Very UnlikelyExtremely Likely
Required
Thank you for your feedback.
Our goal is to create the best possible product, and your thoughts, ideas and suggestions play a major role in helping us identify opportunities to improve.
Advertiser Disclosure
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.